Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | TDO2 | P48775 | 2/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8494132 | 0.87 | IDO1 (0.55) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL24863639 | 0.87 | IDO1 (0.55) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL2693278 | 0.80 | IDO1 (0.64) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL8494184 | 0.79 | IDO1 (0.48) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL14256464 | 0.79 | IDO1 (0.54) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL1542794 | 0.78 | IDO1 (0.77) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL7041168 | 0.77 | IDO1 (0.70) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL9159527 | 0.77 | IDO1 (0.64) | IDO1MAPTL3MBTL1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL7419440 | 0.77 | IDO1 (0.74) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL1461848 | 0.77 | IDO1 (0.64) | IDO1MAPTL3MBTL1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016133217-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE OXINDOLE COMPOUND AND TRIAZOLIUM SALT USED THEREIN AS CATALYST | 国立大学法人名古屋大学 | 2016-08-25 | — | — | WO | disclosed |
| US-20150291658-A1 | NOVEL CHONDRAMIDE DERIVATIVES | HELMOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20120053181-A1 | PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291658-A1 | NOVEL CHONDRAMIDE DERIVATIVES | CFAP410, CNN2, CSGALNACT1 | IDO1 1142/4885MAPT 4398/4885L3MBTL1 4008/4885 |
| US-20120053181-A1 | PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | IDO1 1190/4885MAPT 2633/4885L3MBTL1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.